<DOC>
	<DOCNO>NCT00627588</DOCNO>
	<brief_summary>The primary objective trial ass safety efficacy ProSavin . Patients trial diagnose Parkinson 's disease fail current treatment L-DOPA progress drug-induced dyskinesia . The first stage open-label dose escalation evaluate three dose level ProSavin cohort three patient . Following recommendation DMC study may proceed second stage trial , 12 patient recruit confirm efficacy optimal dose randomize phase study . The efficacy ProSavin assess use Unified Parkinson 's Disease Rating Score ( UPDRS ) . Patients monitor regular interval , primary endpoint efficacy assessment six month treatment . The secondary objective trial ass extent patient ' current therapy ( L-DOPA ) reduce follow administration ProSavin .</brief_summary>
	<brief_title>Phase I/II Study Safety , Efficacy Dose Evaluation ProSavin Treatment Bilateral Idiopathic Parkinson 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<criteria>1 . Willing able give write Informed Consent 2 . Diagnosed bilateral idiopathic PD 3 . Diagnosis PD &gt; five year , use diagnostic criterion core assessment program surgical interventional therapy CAPSIT ( 1999 ) 4 . Males/females 48 65 year 5 . Women must postmenopausal , last menstrual period two year ago 6 . Male patient must agree use least two method contraception least 3 month follow ProSavin administration partner childbearing capacity 7 . Response LDOPA increase dose unacceptable patient due potentiate fluctuation motor function 8 . Hoehn Yahr stage 3 4 9 . UPDRS ( Part III ) 20 60 `` OFF '' state 10 . Stable dose PD medication , include LDOPA , six week prior surgery 11 . Positive response dopaminergic therapy define 50 % improvement UPDRS ( Part III ) `` OFF '' `` ON '' state 12 . Presence motor fluctuation 13 . Willing current treatment withdrawn 24 hour prior surgery therefore `` OFF '' state surgery 14 . Willing LDOPA dosage reduced/withdrawn discretion principal investigator ( PI ) regular interval follow surgery allow assessment ProSavin absence concomitant anti { Parkinsonian medication 15 . Affiliated French social security health care system ( Patients enrol France ) 1 . Major surgery within 28 day prior enrolment 2 . Severe disable dyskinesias &gt; = 51 % day define UPDRS ( Part IV ) 3 . History psychosis current treatment dopamine block agent kind 4 . Severe depression define BDI score &gt; 16 . Any treatment depression limit seretonergic therapy target dopaminergic pathway 5 . Prior treatment tolcapone within six month prior enrollment study , due ability modify dopaminergic pathway brain 6 . History epilepsy comorbid condition Investigator believe present unacceptable health risk patient conjunction procedure protocol 7 . Lifethreatening illness unrelated PD 8 . History stereotactic surgery treatment PD 9 . Premenopausal woman 10 . Alcohol substance abuse 11 . Clinically significant laboratory test abnormality , include full blood count , chemistry panel , liver function test , electrocardiogram ( ECG ) , Chest X ray 12 . Any contraindication undergo MRI scan head 13 . Intercurrent illness infection 28 day prior enrolment 14 . Abnormal MRI finding mega cisterna , septum pellucidum , sign severe cortical subcortical atrophy , brain tumour , vascular disease , trauma arteriovenous malformation ( AVM ) 15 . Prior regular exposure neuroleptic agent 16 . History treatment agent may induce PD PD symptom within last three month prior enrollment 17 . Contraindications use anaesthesia 18 . Treated dopaminergic antagonist six month prior screen 19 . Concurrent antiretroviral therapy would inactivate investigational agent 20 . History investigational agent within 28 day prior ProSavin administration 21 . Participation prior gene transfer therapy study 22 . Enrolment clinical study , condition , include relate PD , throughout duration ProSavin study 23 . Current anticipate treatment anticoagulant therapy use anticoagulation therapy within four week prior surgery 24 . Diagnosis multiple system atrophy ( MSA ) follow assessment autonomic nervous system function ( e.g . blood pressure , difficulty urinate sexual activity ) MRI screen process 25 . Administration subcutaneous rescue remedy apomorphine 26 . Patient unable adhere prescribe Parkinson 's disease treatment regime .</criteria>
	<gender>All</gender>
	<minimum_age>48 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>ProSavin</keyword>
	<keyword>Parkinson 's Disease</keyword>
	<keyword>Gene Therapy</keyword>
</DOC>